To provide a nuanced understanding of the experiences of patients taking GLP-1 RA medication in various health contexts, including those who stopped taking the medication, such as type 2 diabetes and obesity management.
Key Findings:
Approximately 50% of people with obesity discontinue GLP-1 RAs within 12 months, highlighting a significant challenge in long-term treatment adherence.
Participants reported both benefits and trade-offs associated with GLP-1 RA therapy.
Reasons for cessation included intolerable adverse effects, deterioration in kidney function, and pregnancy.
Interpretation:
The study highlights the complexity of patient experiences with GLP-1 RAs, emphasizing the need for better understanding and support for long-term management, including addressing barriers to adherence.
Limitations:
Limited qualitative research on patient experiences with GLP-1 RAs.
Sample may not represent all demographics or experiences of GLP-1 RA users, particularly in terms of socioeconomic status and geographic diversity.
Conclusion:
The findings can inform optimal management practices and policies to support long-term weight management, ultimately improving patient outcomes.
